CD133 circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients

British Journal of Cancer

Volumn 102, Issue 2, 2010, Pages 268-275

  Vroling, L ^a   Lind, J S W ^a   De Haas, R R ^a   Verheul, H M W ^a   Van Hinsbergh, V W M ^a   Broxterman, H J ^a   Smit, E F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis inhibitors; Bevacizumab; Biomarker; CECs; Erlotinib; HPCs; Sorafenib

Indexed keywords

BEVACIZUMAB; CD133 ANTIGEN; ERLOTINIB; ERYTHROPOIETIN; SORAFENIB; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SPECIFICITY; ENDOTHELIUM CELL; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLID TUMOR; TREATMENT RESPONSE;

ADULT; AGED; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLYCOPROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDES; PYRIDINES; QUINAZOLINES; TUMOR MARKERS, BIOLOGICAL;

EID: 75549091170     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605477     Document Type: Article

References (47)

1. Asosingh K, Aldred MA, Vasanji A, Drazba J, Sharp J, Farver C, Comhair SA, Xu W, Licina L, Huang L, nand-Apte B, Yoder MC, Tuder RM, Erzurum SC (2008) Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol 172(3): 615-627
2. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1): 83-95
3. Broxterman HJ, Gotink KJ, Verheul HM (2009) Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12(4-5): 114-126
4. Burt RK, Testori A, Oyama Y, Rodriguez HE, Yaung K, Villa M, Bucha JM, Milanetti F, Sheehan J, Rajamannan N, Pearce WH (2009) Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplant, e-pub ahead of print. doi: 10.1038/bmt.2009.102
5. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, Bhavsar JR, Yoder MC, Haneline LS, Ingram DA (2007) Human CD34(+)AC133(+)VEGFR-2(+) cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 35(7): 1109-1118
6. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L, Laurie SA (2009) Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 27(3): 404-410
7. Diez M, Barbera JA, Ferrer E, Fernandez-Lloris R, Pizarro S, Roca J, Peinado VI (2007) Plasticity of CD133+ cells: role in pulmonary vascular remodeling. Cardiovasc Res 76(3): 517-527
8. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH (2008) Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 14(5): 1407-1412
9. Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, Jain RK (2006) Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 24(9): 1449-1453
10. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104(43): 17069-17074
11. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6(9): 734-745
12. Gabbianelli M, Pelosi E, Montesoro E, Valtieri M, Luchetti L, Samoggia P, Vitelli L, Barberi T, Testa U, Lyman S (1995) Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 86(5): 1661-1670
13. Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, Altorki N, Mittal V (2009) Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 1796(1): 33-40
14. Gatzemeier U, Blumenschein G, Fosella F (2006) Phase II trial of single agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 24, abstr 7002
15. Groen HJ, Smit EF, Dingemans A (2007) A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 25(18-suppl): 7625
16. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25(30): 4743-4750
17. Hirschi KK, Ingram DA, Yoder MC (2008) Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 28(9): 1584-1595
18. Ingram DA, Caplice NM, Yoder MC (2005) Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 106(5): 1525-1531
19. Jain RK, Duda DG (2003) Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell 3(6): 515-516
20. Karrison TG, Maitland ML, Stadler WM, Ratain MJ (2007) Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99(19): 1455-1461
21. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19): 2039-2049
22. Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG (2009) Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101(10): 1717-1723
23. Le Tourneau C, Vidal L, Siu LL (2008) Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist Updat 11(3): 99-109
24. Lind JS, Dingemans AC, Groen HJ, Smit EF (2009a) A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27, abstr 8018
25. Lind JS, Lagerwaard FJ, Smit EF, Senan S (2009b) Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 74(5): 1391-1396
26. Loupakis F, Falcone A, Masi G, Fioravanti A, Kerbel RS, Del TM, Bocci G (2007) Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol 25(13): 1816-1818
27. Manegold C (2008) Bevacizumab for the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 8(5): 689-699
28. Mehra N, Penning M, Maas J, Beerepoot LV, van DN, van Gils CH, Giles RH, Voest EE (2006) Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res 12(16): 4859-4866
29. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV (2007) Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13(9): 2643-2650
30. Pathak AP, Hochfeld WE, Goodman SL, Pepper MS (2008) Circulating and imaging markers for angiogenesis. Angiogenesis 11(4): 321-335
31. Pennell NA, Lynch Jr TJ (2009) Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14(4): 399-411
32. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, Kinzler KW, Lengauer C (2005) Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11(3): 261-262
33. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20): 4593-4599
34. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24): 2542-2550 (Pubitemid 44917502)
35. Schiller J, Lee J, Hanna N, Traynor A, Carbone D (2008) A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 26, abstr 8014
36. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313(5794): 1785-1787
37. Shojaei F, Ferrara N (2008) Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-antiogenic therapies. Drug Resist Updat 11(6): 219-230
38. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216
39. Timmermans F, Plum J, Yoder MC, Ingram DA, Vandekerckhove B, Case J (2008) Endothelial progenitor cells: identity defined? J Cell Mol Med 13(1): 87-102
40. Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F, De Buyzere ML, Gillebert TC, Plum J, Vandekerckhove B (2007) Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 27(7): 1572-1579
41. Verweij J, Therasse P, Eisenhauer E (2009) Cancer clinical trial outcomes: any progress in tumour-size assessment? Eur J Cancer 45(2): 225-227
42. Vroling L, van der Veldt AAM, de Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, van Cruijsen H, Verheul HM, van den Eertwegh AJ, Hoekman K, Boven E, van Hinsbergh VWM, Broxterman HJ (2009) Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 12(1): 69-79
43. Vroling L, Yuana Y, Schuurhuis GJ, van Hinsbergh VWM, Gundy C, de Haas R, van Cruijsen H, Boven E, Hoekman K, Broxterman HJ (2007) VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients. Thromb Haemost 98(2): 440-450
44. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2): 145-147
45. Yoder MC, Ingram DA (2009) Endothelial progenitor cell: ongoing controversy for defining these cells and their role in neoangiogenesis in the murine system. Curr Opin Hematol 16(4): 269-273
46. Zhu AX, Sahani DV, Duda DG, di TE, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepato-cellular carcinoma: a phase II study. J Clin Oncol 27(18): 3027-3035
47. Zurita A, Jonasch E, Wu H, Tran H, Heymach J (2009) Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 115(10): 2346-2354